[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ADAG#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
ADAG — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
0.19
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
-0.01
EPS This/Next Y
-0.07
Price
3.74
Target Price
8.67
Analyst Recom
1
Performance Q
103.78
Upside
-320.7%
Beta
0.52
Ticker: ADAG
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | ADAG | 2.96 | N/A | N/A | 0 |
| 2026-03-02 | ADAG | 2.98 | N/A | N/A | 0 |
| 2026-03-03 | ADAG | 2.98 | N/A | N/A | 0 |
| 2026-03-04 | ADAG | 2.92 | N/A | N/A | 0 |
| 2026-03-05 | ADAG | 3.03 | N/A | N/A | 0 |
| 2026-03-06 | ADAG | 3.06 | N/A | N/A | 0 |
| 2026-03-09 | ADAG | 3.01 | N/A | N/A | 0 |
| 2026-03-10 | ADAG | 2.91 | N/A | N/A | 0 |
| 2026-03-11 | ADAG | 3.53 | N/A | N/A | 0 |
| 2026-03-12 | ADAG | 3.51 | N/A | N/A | 0 |
| 2026-03-13 | ADAG | 3.56 | N/A | N/A | 0 |
| 2026-03-17 | ADAG | 3.9 | N/A | N/A | 0 |
| 2026-03-18 | ADAG | 3.97 | N/A | N/A | 0 |
| 2026-03-19 | ADAG | 3.74 | N/A | N/A | 0 |
| 2026-03-20 | ADAG | 3.56 | N/A | N/A | 0 |
| 2026-03-23 | ADAG | 3.94 | N/A | N/A | 0 |
| 2026-03-24 | ADAG | 3.55 | N/A | N/A | 0 |
| 2026-03-25 | ADAG | 3.99 | N/A | N/A | 0 |
| 2026-03-26 | ADAG | 4.08 | N/A | N/A | 0 |
| 2026-03-27 | ADAG | 3.72 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | ADAG | 3.05 | - | - | -0.65 |
| 2026-03-02 | ADAG | 2.99 | - | - | -0.65 |
| 2026-03-03 | ADAG | 3.04 | - | - | -0.65 |
| 2026-03-04 | ADAG | 3.00 | - | - | -0.65 |
| 2026-03-05 | ADAG | 2.85 | - | - | -0.65 |
| 2026-03-06 | ADAG | 2.94 | - | - | -0.65 |
| 2026-03-09 | ADAG | 3.00 | - | - | -0.65 |
| 2026-03-10 | ADAG | 2.98 | - | - | -0.65 |
| 2026-03-11 | ADAG | 3.55 | - | - | -0.65 |
| 2026-03-12 | ADAG | 3.56 | - | - | -0.65 |
| 2026-03-13 | ADAG | 4.20 | - | - | -0.65 |
| 2026-03-17 | ADAG | 3.91 | - | - | -0.65 |
| 2026-03-18 | ADAG | 3.96 | - | - | -0.65 |
| 2026-03-19 | ADAG | 3.73 | - | - | -0.65 |
| 2026-03-20 | ADAG | 3.63 | - | - | -0.65 |
| 2026-03-23 | ADAG | 3.90 | - | - | -0.65 |
| 2026-03-24 | ADAG | 3.46 | - | - | -0.65 |
| 2026-03-25 | ADAG | 4.00 | - | - | -0.65 |
| 2026-03-26 | ADAG | 4.13 | - | - | -0.65 |
| 2026-03-27 | ADAG | 3.74 | - | - | -0.65 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | ADAG | 0.00 | -10.23 | 0.12 |
| 2026-03-02 | ADAG | 0.00 | -10.25 | 0.12 |
| 2026-03-03 | ADAG | 0.00 | -10.25 | 0.12 |
| 2026-03-04 | ADAG | 0.00 | -10.25 | 0.12 |
| 2026-03-05 | ADAG | 0.00 | -10.25 | 0.12 |
| 2026-03-06 | ADAG | 0.00 | -10.25 | 0.12 |
| 2026-03-09 | ADAG | 0.00 | -10.25 | 0.12 |
| 2026-03-10 | ADAG | 0.00 | -10.25 | 0.12 |
| 2026-03-11 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-12 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-13 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-17 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-18 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-19 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-20 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-23 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-24 | ADAG | 0.00 | -10.25 | 0.13 |
| 2026-03-25 | ADAG | 0.00 | -10.25 | 0.19 |
| 2026-03-26 | ADAG | 0.00 | -10.25 | 0.19 |
| 2026-03-27 | ADAG | 0.00 | -10.25 | 0.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ADAG 589 360 ]
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.15
Avg. EPS Est. Next Quarter
-0.19
Insider Transactions
Institutional Transactions
-10.25
Beta
0.52
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
23
Growth Score
23
Sentiment Score
94
Actual DrawDown %
82.2
Max Drawdown 5-Year %
-95.6
Target Price
8.67
P/E
Forward P/E
PEG
P/S
1776.8
P/B
4.69
P/Free Cash Flow
EPS
-0.64
Average EPS Est. Cur. Y
-0.65
EPS Next Y. (Est.)
-0.72
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-28963.53
Relative Volume
0.73
Return on Equity vs Sector %
-106.2
Return on Equity vs Industry %
-89.9
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ADAG 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ADAG 589 450 ]
◆
ADAG
Healthcare
$3.77
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
55.5
Range 1M
50%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
15.3%
EPS NY
-28%
52W%
72.6%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+130% upside
Upside
+130%
Quality
23
Adagene Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 138
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
ADAG
Latest News
—
Caricamento notizie per ADAG…
stock quote shares ADAG – Adagene Inc. Stock Price stock today
news today ADAG – Adagene Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ADAG – Adagene Inc. yahoo finance google finance
stock history ADAG – Adagene Inc. invest stock market
stock prices ADAG premarket after hours
ticker ADAG fair value insiders trading